Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis

NCT: NCT07293871 · RECRUITING

NCT IDNCT07293871
StatusRECRUITING
Start Date2026-03-20
Completion2027-04
SponsorSurf Therapeutics (INDUSTRY)
First posted
Last updated

Brief Summary

This two-stage, multicenter clinical trial is designed to evaluate the feasibility, safety, and preliminary efficacy of splenic ultrasound stimulation to activate immune-neuromodulation (SUSTAIN) in patients with rheumatoid arthritis (RA) and at least moderate disease activity. The findings from this trial will directly inform the design and power calculations for a future pivotal trial by identifying an appropriate effect size and confirming protocol feasibility and safety.

Frequently Asked Questions

What is Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis?

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis is a clinical trial registered under NCT07293871. Current status: RECRUITING.

What is the status of NCT07293871?

The current status of NCT07293871 (Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis) is: RECRUITING.

When did Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis start?

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis started on 2026-03-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.